PCB exposure in utero and via breast milk. A review

E P DeKoning1, W Karmaus

  • 1Department of Epidemiology, Michigan State University, East Lansing 48823, USA. dekonin1@pilot.msu.edu

Insights

Polychlorinated biphenyl (PCB) exposure during pregnancy and breastfeeding is significant for offspring. Our review suggests PCBs cross the placenta more than expected, highlighting the need for comprehensive perinatal monitoring.

Area of Science:

  • Environmental Health
  • Toxicology
  • Perinatal Studies

Background:

  • Polychlorinated biphenyls (PCBs) are persistent organic pollutants with known health risks.
  • Exposure to PCBs can occur in utero and through breast milk, potentially impacting offspring development.
  • Understanding PCB distribution in maternal and fetal tissues is crucial for risk assessment.

Purpose of the Study:

  • To review existing literature on in utero and breast milk polychlorinated biphenyl (PCB) exposure in relation to offspring health.
  • To compare PCB concentrations across maternal and fetal tissues, including placenta, breast milk, maternal blood, and cord blood.
  • To assess the extent to which PCBs transfer across the placenta.

Main Methods:

  • A comprehensive literature review was conducted, identifying 25 relevant reports from 16 study populations.
  • Tissue-specific PCB concentrations were analyzed on a lipid basis for placenta, breast milk, maternal blood, and cord blood.
  • Accumulation ratios between different tissue compartments were calculated.

Main Results:

  • The highest PCB concentration in placenta (5027 ng/g fat) was 2.8 times higher than in breast milk (1770 ng/g fat) on a lipid basis.
  • Results suggest that PCBs may cross the placenta to a greater extent than previously understood.
  • Limitations in quantitation and statistical methods were noted across the reviewed studies.

Conclusions:

  • Perinatal PCB exposure is a significant concern for offspring health.
  • Placental transfer of PCBs appears substantial, warranting further investigation.
  • Future studies should include placenta, breast milk, maternal, and cord blood for comprehensive PCB body burden assessment.
  • Standardizing PCB concentration measurements on a lipid basis is recommended for comparability across studies.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...